Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $58.11 Consensus Price Target from Brokerages

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have been given an average rating of “Buy” by the fourteen analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $58.1111.

A number of equities research analysts recently weighed in on the stock. Citizens Jmp lifted their price objective on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a report on Thursday, December 11th. Leerink Partners started coverage on shares of Terns Pharmaceuticals in a research report on Monday, February 9th. They set an “outperform” rating and a $58.00 target price on the stock. Barclays boosted their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. BMO Capital Markets raised their price objective on Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Terns Pharmaceuticals in a research report on Wednesday, November 26th.

Terns Pharmaceuticals Trading Down 0.2%

NASDAQ:TERN opened at $41.38 on Thursday. Terns Pharmaceuticals has a twelve month low of $1.87 and a twelve month high of $48.26. The company has a market cap of $4.29 billion, a price-to-earnings ratio of -40.17 and a beta of -0.28. The stock has a fifty day simple moving average of $38.14 and a 200-day simple moving average of $23.16.

Insider Activity

In related news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the sale, the insider directly owned 50,365 shares of the company’s stock, valued at $1,942,578.05. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amy L. Burroughs sold 14,583 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $39.19, for a total transaction of $571,507.77. Following the transaction, the chief executive officer directly owned 288,976 shares in the company, valued at $11,324,969.44. This trade represents a 4.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 155,826 shares of company stock valued at $5,882,597 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Terns Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Terns Pharmaceuticals during the 4th quarter worth $25,000. GAMMA Investing LLC boosted its holdings in Terns Pharmaceuticals by 762.4% in the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Terns Pharmaceuticals by 61.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock worth $89,000 after acquiring an additional 841 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Terns Pharmaceuticals by 5.1% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 18,555 shares of the company’s stock worth $750,000 after acquiring an additional 906 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Terns Pharmaceuticals by 29.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,377 shares of the company’s stock valued at $177,000 after acquiring an additional 994 shares in the last quarter. Institutional investors own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.